Key result
Maternal administration of propranolol for a fetus with familial hypertrophic cardiomyopathy reduced septal thickness from 8.8 mm at 35 weeks gestation to 7.6 mm at 38 weeks, with normalization in infancy.
Why the study?
Does maternal propranolol administration improve septal hypertrophy and diastolic dysfunction in a fetus with familial hypertrophic cardiomyopathy?
Case Report (n=1)
No
Does maternal propranolol administration improve septal hypertrophy and diastolic dysfunction in a fetus with familial hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Maternal administration of propranolol may be a viable intrauterine treatment to reduce septal hypertrophy in fetuses with familial hypertrophic cardiomyopathy and diastolic dysfunction.
There is no clear consensus on optimal management of fetuses affected by familial hypertrophic cardiomyopathy (HCM). Intrauterine treatment of the condition has not been attempted in any standardized fashion. We report the case of a fetus treated by maternal propranolol during the third trimester after septal hypertrophy and diastolic dysfunction was diagnosed on fetal echocardiogram. The pregnancy went successfully to term, and fetal septal hypertrophy was noted to improve prior to delivery.
No takes yet. Share an insight, caveat, or question.
Hill et al. (2015) conducted a case report in Familial hypertrophic cardiomyopathy (n=1). Propranolol was evaluated on Interventricular septal thickness in diastole (IVSd). Maternal administration of propranolol for a fetus with familial hypertrophic cardiomyopathy reduced septal thickness from 8.8 mm at 35 weeks gestation to 7.6 mm at 38 weeks, with normalization in infancy.
Synapse has enriched 10 related papers. Consider them for comparative context: